LABT (Lakewood-Amedex Biotherapeutics) Pretax Margin %: % (As of Mar. 2026)


LABT Lakewood-Amedex Biotherapeutics Inc LABT
8 GF Score
Price $3.55
View Full Analysis

What is Lakewood-Amedex Biotherapeutics Pretax Margin %?

Lakewood-Amedex Biotherapeutics LABT +2.33% 8 Pretax Margin % is % as of Mar. 2026. GuruFocus rates LABT with a GF Score™ of 8/100. Among 946 Biotechnology companies, Lakewood-Amedex Biotherapeutics ranks worse than 105708.14% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Lakewood-Amedex Biotherapeutics's Pre-Tax Income for the three months ended in Mar. 2026 was $-0.92 Mil. Lakewood-Amedex Biotherapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Lakewood-Amedex Biotherapeutics's pretax margin for the quarter that ended in Mar. 2026 was %.

The historical rank and industry rank for Lakewood-Amedex Biotherapeutics's Pretax Margin % or its related term are showing as below:


LABT's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.5
* Ranked among companies with meaningful Pretax Margin % only.

Lakewood-Amedex Biotherapeutics  (NAS:LABT) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Lakewood-Amedex Biotherapeutics Pretax Margin % Related Terms


Lakewood-Amedex Biotherapeutics Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Lakewood-Amedex Biotherapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakewood-Amedex Biotherapeutics Pretax Margin % Chart

Lakewood-Amedex Biotherapeutics Annual Data
Trend Dec23 Dec24 Dec25
Pretax Margin %
0.00 0.00 0.00

Lakewood-Amedex Biotherapeutics Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

LABT vs CURX, PBM, NCNA: Pretax Margin % Comparison

For the Biotechnology subindustry, Lakewood-Amedex Biotherapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lakewood-Amedex Biotherapeutics Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lakewood-Amedex Biotherapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Lakewood-Amedex Biotherapeutics's Pretax Margin % falls into.


LABT
8GF Score
Lakewood-Amedex Biotherapeutics Inc LABT
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakewood-Amedex Biotherapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Lakewood-Amedex Biotherapeutics's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.848/0
= %

Lakewood-Amedex Biotherapeutics's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.923/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Lakewood-Amedex Biotherapeutics (LABT) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. According to the industry distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 946 companies in the Biotechnology industry.
Is Lakewood-Amedex Biotherapeutics' Pretax Margin % too high?
Lakewood-Amedex Biotherapeutics' current Pretax Margin % is %. Based on the distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Pretax Margin % compare to CURX and PBM?
According to the Biotechnology industry distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 946 companies for Pretax Margin %. This places Lakewood-Amedex Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. Lakewood-Amedex Biotherapeutics's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Pretax Margin % of %. The current Pretax Margin % is %. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lakewood-Amedex Biotherapeutics Business Description

Address 8031 Cooper Creek Blvd, Unit 103, University Park, FL, USA, 34201
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score

Get the complete analysis for LABT

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price